RENOVARO INC. - COMMON STOCK

Statement of Renovaro Inc

14 Feb 2024 10:01:30 By Nasdaq GlobeNewswire

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

13 Feb 2024 09:46:07 By Nasdaq GlobeNewswire

AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

13 Feb 2024 09:31:09 By Nasdaq GlobeNewswire

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

25 Jan 2024 12:45:00 By Nasdaq GlobeNewswire

Message from Renovaro Bioscience, Inc.’s CEO, The Hon. Mark Dybul, MD

16 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors

11 Oct 2023 09:25:00 By Nasdaq GlobeNewswire

Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors

10 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD

02 Oct 2023 12:05:40 By Nasdaq GlobeNewswire

AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine

02 Oct 2023 09:25:00 By Nasdaq GlobeNewswire

Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine

29 Sep 2023 09:15:00 By Nasdaq GlobeNewswire

Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort

30 Aug 2023 09:15:00 By Nasdaq GlobeNewswire

Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer

21 Aug 2023 09:15:00 By Nasdaq GlobeNewswire

AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer

09 Aug 2023 09:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting

23 Jun 2023 17:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

08 Jun 2023 08:45:00 By Nasdaq GlobeNewswire

Enochian BioSciences’ CEO Letter to Shareholders

03 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher

29 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements

13 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

23 Feb 2023 16:04:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022

30 Nov 2022 17:20:12 By Nasdaq GlobeNewswire